

Colorado C.R.S. 12-280-308 Disclosure

LAGEVRIO™ (molnupiravir)

Merck Sharp & Dohme LLC (“Merck”) provides the following information to Colorado prescribers, as required by C.R.S. 12-280-308.

The pricing information below reflects Merck’s Wholesale Acquisition Costs (“WAC”) for the Merck product. The WAC represents published catalogue or list price and may not represent actual transactional prices. The price a customer pays may vary from the prices listed, depending, for example, on how the customer purchases the product, the availability of discounts, the wholesaler/distributor, or other charges.

WAC for Merck Product

PRODUCT	NDC	DOSAGE FORM AND STRENGTH	WHOLESALE ACQUISITION COST (WAC)
LAGEVRIO™ (molnupiravir) 200 mg Capsules	00006-5055-09	Unit-of-use bottle of 40	\$997.20

LAGEVRIO™ has not been approved, but has been authorized for emergency use by the FDA under an Emergency Use Authorization (EUA), for the treatment of adults with mild-to-moderate COVID-19, who are at high risk for progression to severe COVID-19, including hospitalization or death, and for whom alternative COVID-19 treatment options approved or authorized by FDA are not accessible or clinically appropriate.

The emergency use of LAGEVRIO™ is only authorized for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of drugs and biological products during the COVID-19 pandemic under Section 564(b)(1) of the FDA Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization revoked sooner.

Before prescribing LAGEVRIO™, please read the accompanying [Fact Sheet for Healthcare Providers](#), including Mandatory Requirements for Administration of LAGEVRIO Under Emergency Use Authorization. The [FDA Letter of Authorization](#) and the [Fact Sheet for Patients and Caregivers](#) are also available.

The list below provides names of generic prescription drugs from the same therapeutic class as the Merck product, in accordance with Colorado law. Note that the drugs listed are not necessarily the generic form of the Merck product. Rather, these drugs could be the generic form of a non-Merck drug from the same therapeutic class. Depending on the number of generic prescription drugs in the therapeutic class, this list may not be inclusive of all.

This list does not imply that the products on this chart are interchangeable or have the same efficacy or safety. Please refer to each product’s FDA-approved label and indication for further information.

Generic Prescription Drugs from the Same Therapeutic Class*

acyclovir	adefovir dipivoxil	famciclovir	ribavirin
acyclovir sodium	cidofovir	ganciclovir	valacyclovir HCl
acyclovir sodium in 0.9 % sodium chloride	entecavir	ganciclovir sodium	

* Source: Generic Prescription Drug Data Extracted from AnalySource, 1/1/2025. Reprinted with permission by First Databank Inc. All rights reserved. © 2025.

For purposes of listing the generic prescription drugs above, the Therapeutic Class is derived from the American Hospital Formulary Service Pharmacologic Therapeutic Classification system, published by the American Society of Health System Pharmacists.

The trademarks or service marks herein are owned by, licensed to, promoted by, or distributed by Merck & Co., Inc., its subsidiaries or its affiliates.

Copyright © 2025 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.

US-ANV-00769 01/25